Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 12/20 | 1.00 |
| ▸ | HDAC3 | O15379 | 12/20 | 1.00 |
| ▸ | HDAC8 | Q9BY41 | 12/20 | 1.00 |
| ▸ | HDAC4 | P56524 | 12/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 12/20 | 1.00 |
| ▸ | HDAC2 | Q92769 | 10/20 | 1.00 |
| ▸ | HDAC9 | Q9UKV0 | 9/20 | 1.00 |
| ▸ | HDAC5 | Q9UQL6 | 9/20 | 1.00 |
| ▸ | HDAC7 | Q8WUI4 | 8/20 | 1.00 |
| ▸ | HDAC10 | Q969S8 | 8/20 | 1.00 |
| ▸ | HDAC11 | Q96DB2 | 8/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.53 |
| ▸ | CTSL | P07711 | 2/20 | 0.52 |
| ▸ | CTSB | P07858 | 2/20 | 0.52 |
| ▸ | MEF2D | Q14814 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3921684 | 1.00 | HDAC6 (1.00) | HDAC6HDAC3HDAC8HDAC4HDAC1 | |
| SCHEMBL7259047 | 0.92 | HDAC6 (0.84) | HDAC6HDAC3HDAC8HDAC4HDAC1 | |
| SCHEMBL3919380 | 0.85 | HDAC6 (0.73) | HDAC6HDAC3HDAC8HDAC4HDAC1 | |
| SCHEMBL3919379 | 0.85 | HDAC6 (0.73) | HDAC6HDAC3HDAC8HDAC4HDAC1 | |
| SCHEMBL3918069 | 0.83 | HDAC1 (0.80) | HDAC6HDAC3HDAC8HDAC4HDAC1 | |
| SCHEMBL3918071 | 0.83 | HDAC1 (0.80) | HDAC6HDAC3HDAC8HDAC4HDAC1 | |
| SCHEMBL3919573 | 0.81 | HDAC6 (0.67) | HDAC6HDAC3HDAC8HDAC4HDAC1 | |
| SCHEMBL30598713 | 0.81 | HDAC1 (0.73) | HDAC6HDAC3HDAC8HDAC4HDAC1 | |
| SCHEMBL3927969 | 0.80 | HDAC1 (1.00) | HDAC6HDAC3HDAC8HDAC4HDAC1 | |
| SCHEMBL3926505 | 0.80 | HDAC1 (0.72) | HDAC6HDAC3HDAC8HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025106604-A1 | COMPOSITIONS AND METHODS RELATING TO ANTIVIRAL THERAPEUTICS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2025-05-22 | — | — | WO | claimed |
| US-12187698-B2 | Crystalline forms of C21H22Cl2N4O2 | BIOMED VALLEY DISCOVERIES, INC. (US) | 2025-01-07 | — | — | US | claimed |
| US-20220324832-A1 | CRYSTALLINE FORMS OF C21H22Cl2N4O2 | VERTEX PHARMACEUTICALS INCORPORATED | 2022-10-13 | — | — | US | claimed |
| CN-114632159-A | Antitumor composition and application thereof | 澳门科技大学 | 2022-06-17 | — | — | CN | claimed |
| US-10813919-B2 | Use of histone deacetylase inhibitors for enhancing immunotherapies | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2020-10-27 | — | — | US | claimed |
| US-20190030011-A1 | USE OF HISTONE DEACETYLASE INHIBITORS FOR ENHANCING IMMUNOTHERAPIES | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2019-01-31 | — | — | US | claimed |
| US-7495022-B2 | α,β-unsaturated hydroxamic acid derivatives and their use as histone deacetylase inhibitors | SK CHEMICALS CO., LTD. (KR) | 2009-02-24 | — | — | US | claimed |
| US-20050124679-A1 | Alpha, beta-unsaturated hydroxamic acid derivatives and their use as histone deacetylase inhibitors | SK CHEMICALS CO., LTD. (KR) | 2005-06-09 | — | — | US | claimed |
| US-20260000714-A1 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN NON-HUMAN ANIMALS | BIOMED VALLEY DISCOVERIES INC (US) | 2026-01-01 | — | — | US | disclosed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| EP-4653054-A2 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN HUMANS | Biomed Valley Discoveries, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| US-12433920-B2 | C. novyi for the treatment of solid tumors in non-human animals | BIOMED VALLEY DISCOVERIES, INC. (US) | 2025-10-07 | — | — | US | disclosed |
| EP-4108248-B1 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN HUMANS | BIOMED VALLEY DISCOVERIES INC (US) | 2025-09-17 | — | — | EP | disclosed |
| WO-2025106604-A1 | COMPOSITIONS AND METHODS RELATING TO ANTIVIRAL THERAPEUTICS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2025-05-22 | — | — | WO | disclosed |
| EP-3730146-B1 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN HUMANS | BIOMED VALLEY DISCOVERIES INC (US) | 2022-05-04 | — | — | EP | disclosed |
| US-10813919-B2 | Use of histone deacetylase inhibitors for enhancing immunotherapies | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2020-10-27 | — | — | US | disclosed |
| US-20190030011-A1 | USE OF HISTONE DEACETYLASE INHIBITORS FOR ENHANCING IMMUNOTHERAPIES | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2019-01-31 | — | — | US | disclosed |
| US-7495022-B2 | α,β-unsaturated hydroxamic acid derivatives and their use as histone deacetylase inhibitors | SK CHEMICALS CO., LTD. (KR) | 2009-02-24 | — | — | US | disclosed |
| US-20050124679-A1 | Alpha, beta-unsaturated hydroxamic acid derivatives and their use as histone deacetylase inhibitors | SK CHEMICALS CO., LTD. (KR) | 2005-06-09 | — | — | US | disclosed |
| WO-2003087066-A1 | α,β-UNSATURATED HYDROXAMIC ACID DERIVATIVES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS | SK CHEMICALS, CO., LTD. (KR) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324832-A1 | CRYSTALLINE FORMS OF C21H22Cl2N4O2 | CYP2F1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CA4 | HDAC6 777/4885HDAC3 2519/4885HDAC8 3157/4885 |
| US-12433920-B2 | C. novyi for the treatment of solid tumors in non-human animals | MKI67, HCCS, NCF1 | HDAC6 3067/4885HDAC3 3133/4885HDAC8 3258/4885 |
| US-12187698-B2 | Crystalline forms of C21H22Cl2N4O2 | CYP2F1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CA4 | HDAC6 777/4885HDAC3 2519/4885HDAC8 3157/4885 |
| US-20260000714-A1 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN NON-HUMAN ANIMALS | KIT, CPA3, MKI67 | HDAC6 3131/4885HDAC3 3272/4885HDAC8 2243/4885 |
| US-20050124679-A1 | Alpha, beta-unsaturated hydroxamic acid derivatives and their use as histone deacetylase inhibitors | HDAC1, HDAC5, HDAC9 | HDAC6 10/4885HDAC3 8/4885HDAC8 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.